XML 38 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Payment Transactions
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
SHARE-BASED PAYMENT TRANSACTIONS

NOTE 11:- SHARE-BASED PAYMENT TRANSACTIONS

 

  a. Share options plan:

 

On November 28, 2013, the board of directors approved the adoption of the 2013 Share Option Plan (the “2013 Plan”). Under the 2013 Plan, the Company may grant its officers, directors, employees and consultants, stock options, of the Company. Each stock option granted shall be exercisable at such times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will be granted with a term in excess of 10 years.

 

Under the Company’s 2013 Plan, in July 2022, the Company’s Board of Directors approved to increase number of ordinary shares reserved for issuance to 35,000,000. As of December 31, 2022, 8,023,000 shares available for future grant under the 2013 Plan.

 

  b. Expenses recognized in the financial statements:

 

   Year ended December 31, 
   2022   2021   2020 
             
Research and development expenses  $137   $200   $159 
General and administrative expenses   126    266    158 
    263    466    317 

 

  c. Share-based payment transactions granted by the Company:

 

The fair value of the Company’s share options granted was estimated using the binomial option pricing model using the following range assumptions:

 

Description  2022   2021   2020 
             
Risk-free interest rate   1.41%-3.08%    1.22-1.28%    0.93-2.40% 
Expected volatility   83.98%-84.26%     82.40-82.43%    65.63-78.77% 
Dividend yield   0    0    0 
Contractual life   10    10    9.83 - 10 
Early Exercise Multiple (Suboptimal Factor)   2.5-3    3    2.5 - 3 
Exercise price (NIS)   0.25    0.25-0.253    0.25 - 2.344 

 

    Movement during the year:

 

The following table lists the number of share options, their weighted average exercise prices and modification in option plans of employees, directors and consultants for the year ended December 31, 2022 and related information:

 

   Number of
options		   Weighted
average
exercise
price		   Weighted
average
remaining
contractual
terms (in years)		   Aggregate
intrinsic
value		 
                 
Outstanding at December 31, 20221   18,422,700    0.18    8.45    
      -
 
Grants   8,750,000    0.07    
 
    
 
 
Forfeited/expired   (170,500)   0.54    
-
    
 
 
                     
Outstanding at December 31, 2022   27,002,200    0.13    7.14    
-
 
                     
Vested and expected to vest at December 31, 2022   27,002,200    0.13    7.14    
-
 
                     
Exercisable at December 31, 2022   11,071,575    0.21    7.18    
-
 

 

  d. The weighted average remaining contractual life for the shares subject to options outstanding as of December 31, 2022, 2021 and 2020 was 6.96 years, 8.45 years and 6.98 years, respectively.

 

  e. The weighted average grant date fair value in 2022 was $0.02 and in 2021 was $0.18 and the remaining compensation costs not yet recognized as of December 31, 2022 is $230 with a weighted average period of 2.73 years to recognize these expenses.